Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Usi

Gavai, Ashvinikumar V.; Norris, Derek; Delucca, George; Tortolani, David; Tokarski, John S.; Dodd, Dharmpal; O?Malley, Daniel; Zhao, Yufen; Quesnelle, Claude; Gill, Patrice; Vaccaro, Wayne; Huynh, Tram; Ahuja, Vijay; Han, Wen-Ching; Mussari, Christopher; Harikrishnan, Lalgudi; Kamau, Muthoni; Poss, Michael; Sheriff, Steven; Yan, Chunhong; Marsilio, Frank; Menard, Krista; Wen, Mei-Li; Rampulla, Richard; Wu, Dauh-Rurng; Li, Jianqing; Zhang, Huiping; Li, Peng; Sun, Dawn; Yip, Henry; Traeger, Sarah C.; Zhang, Yingru; Mathur, Arvind; Zhang, Haiying; Huang, Christine; Yang, Zheng; Ranasinghe, Asoka; Everlof, Gerry; Raghavan, Nirmala; Tye, Ching Kim; Wee, Susan; Hunt, John T.; Vite, Gregory; Westhouse, Richard; Lee, Francis Y.

doi:10.1021/acs.jmedchem.1c00625

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Usi

Journal Article · Wed Sep 01 04:00:00 EDT 2021 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.1c00625· OSTI ID:1834907

Gavai, Ashvinikumar V.; Norris, Derek; Delucca, George; Tortolani, David; Tokarski, John S.; Dodd, Dharmpal; O?Malley, Daniel; Zhao, Yufen; Quesnelle, Claude; Gill, Patrice; Vaccaro, Wayne; Huynh, Tram; Ahuja, Vijay; Han, Wen-Ching; Mussari, Christopher; Harikrishnan, Lalgudi; Kamau, Muthoni; Poss, Michael; Sheriff, Steven; Yan, Chunhong more »

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1834907

Journal Information:: J. Med. Chem., Journal Name: J. Med. Chem. Journal Issue: (19) Vol. 64

Country of Publication:: United States

Language:: ENGLISH

References (31)

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins Lockwood, W. W.; Zejnullahu, K.; Bradner, J. E. Proceedings of the National Academy of Sciences, Vol. 109, Issue 47 https://doi.org/10.1073/pnas.1216363109	journal	November 2012
Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
[20] Processing of X-ray diffraction data collected in oscillation mode Otwinowski, Zbyszek; Minor, Wladek Macromolecular Crystallography Part A, 307-326 https://doi.org/10.1016/S0076-6879(97)76066-X	book	January 1997
Bromodomain: an acetyl-lysine binding domain Zeng, Lei; Zhou, Ming-Ming FEBS Letters, Vol. 513, Issue 1 https://doi.org/10.1016/S0014-5793(01)03309-9	journal	January 2002
Integration, scaling, space-group assignment and post-refinement Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 133-144 https://doi.org/10.1107/S0907444909047374	journal	January 2010
Achieving clinical success with BET inhibitors as anti-cancer agents Shorstova, Tatiana; Foulkes, William D.; Witcher, Michael British Journal of Cancer, Vol. 124, Issue 9 https://doi.org/10.1038/s41416-021-01321-0	journal	March 2021
Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters Orjales, Aurelio; Mosquera, Ramón; Toledo, Antonio Journal of Medicinal Chemistry, Vol. 46, Issue 25 https://doi.org/10.1021/jm0309349	journal	November 2003
Scaling and assessment of data quality Evans, Philip Acta Crystallographica Section D Biological Crystallography, Vol. 62, Issue 1, p. 72-82 https://doi.org/10.1107/S0907444905036693	journal	December 2005
Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds Hitchcock, Stephen A. Journal of Medicinal Chemistry, Vol. 55, Issue 11 https://doi.org/10.1021/jm201136z	journal	April 2012
Phaser crystallographic software McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D. Journal of Applied Crystallography, Vol. 40, Issue 4 https://doi.org/10.1107/S0021889807021206	journal	July 2007
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches Wong, C. C.; Qian, Y.; Yu, J. Oncogene, Vol. 36, Issue 24 https://doi.org/10.1038/onc.2016.485	journal	January 2017
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers Lovén, Jakob; Hoke, Heather A.; Lin, Charles Y. Cell, Vol. 153, Issue 2 https://doi.org/10.1016/j.cell.2013.03.036	journal	April 2013
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments Madhavi Sastry, G.; Adzhigirey, Matvey; Day, Tyler Journal of Computer-Aided Molecular Design, Vol. 27, Issue 3 https://doi.org/10.1007/s10822-013-9644-8	journal	March 2013
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells Coudé, Marie-Magdelaine; Braun, Thorsten; Berrou, Jeannig Oncotarget, Vol. 6, Issue 19 https://doi.org/10.18632/oncotarget.4131	journal	May 2015
Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions Hewings, David S.; Rooney, Timothy P. C.; Jennings, Laura E. Journal of Medicinal Chemistry, Vol. 55, Issue 22 https://doi.org/10.1021/jm300915b	journal	September 2012
Functions of Site-Specific Histone Acetylation and Deacetylation Shahbazian, Mona D.; Grunstein, Michael Annual Review of Biochemistry, Vol. 76, Issue 1 https://doi.org/10.1146/annurev.biochem.76.052705.162114	journal	June 2007
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Zuber, Johannes; Shi, Junwei; Wang, Eric Nature, Vol. 478, Issue 7370 https://doi.org/10.1038/nature10334	journal	August 2011
Suppression of inflammation by a synthetic histone mimic Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe Nature, Vol. 468, Issue 7327 https://doi.org/10.1038/nature09589	journal	November 2010
Refinement of severely incomplete structures with maximum likelihood in BUSTER–TNT Blanc, E.; Roversi, P.; Vonrhein, C. Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12 https://doi.org/10.1107/S0907444904016427	journal	November 2004
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma Cheng, Zhixiang; Gong, Yuanying; Ma, Yufang Clinical Cancer Research, Vol. 19, Issue 7 https://doi.org/10.1158/1078-0432.CCR-12-3066	journal	February 2013
Targeting MYC dependence in cancer by inhibiting BET bromodomains Mertz, J. A.; Conery, A. R.; Bryant, B. M. Proceedings of the National Academy of Sciences, Vol. 108, Issue 40 https://doi.org/10.1073/pnas.1108190108	journal	September 2011
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Wyce, Anastasia; Degenhardt, Yan; Bai, Yuchen Oncotarget, Vol. 4, Issue 12 https://doi.org/10.18632/oncotarget.1572	journal	November 2013
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer Shimamura, Takeshi; Chen, Zhao; Soucheray, Margaret Clinical Cancer Research, Vol. 19, Issue 22 https://doi.org/10.1158/1078-0432.CCR-12-3904	journal	September 2013
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E. Cell, Vol. 146, Issue 6 https://doi.org/10.1016/j.cell.2011.08.017	journal	September 2011
Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression Lenhart, Ryan; Kirov, Stefan; Desilva, Heshani Molecular Cancer Therapeutics, Vol. 14, Issue 10 https://doi.org/10.1158/1535-7163.MCT-15-0037	journal	August 2015
Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility Grochulski, Pawel; Fodje, Michel N.; Gorin, James Journal of Synchrotron Radiation, Vol. 18, Issue 4 https://doi.org/10.1107/S0909049511019431	journal	June 2011
Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer Gavai, Ashvinikumar V.; Norris, Derek; Tortolani, David Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL, Experimental and Molecular Therapeutics https://doi.org/10.1158/1538-7445.AM2018-5789	conference	July 2018
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Dawson, Mark A.; Prinjha, Rab K.; Dittmann, Antje Nature, Vol. 478, Issue 7370 https://doi.org/10.1038/nature10509	journal	October 2011
Selective inhibition of BET bromodomains Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah Nature, Vol. 468, Issue 7327 https://doi.org/10.1038/nature09504	journal	September 2010
BET inhibitor resistance emerges from leukaemia stem cells Fong, Chun Yew; Gilan, Omer; Lam, Enid Y. N. Nature, Vol. 525, Issue 7570 https://doi.org/10.1038/nature14888	journal	September 2015
The bromodomain interaction module Filippakopoulos, Panagis; Knapp, Stefan FEBS Letters, Vol. 586, Issue 17 https://doi.org/10.1016/j.febslet.2012.04.045	journal	May 2012

Similar Records

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Usi

Journal Article · Wed Sep 01 00:00:00 EDT 2021 · J. Med. Chem. · OSTI ID:1832563

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor

Journal Article · Sat Jun 16 20:00:00 EDT 2018 · Journal of Medicinal Chemistry · OSTI ID:1471643

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors

Journal Article · Fri Mar 24 00:00:00 EDT 2017 · Journal of Medicinal Chemistry · OSTI ID:1400312

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Usi

Citation Formats

References (31)

Similar Records

Related Subjects